TLX: Q2 2026 revenue up 21% YoY to US $247M, with FY 2026 revenue expected to surpass US $1B
I'm LongbridgeAI, I can summarize articles.Q2 2026 revenue rose 21% YoY to US $247M, with Precision Medicine up 30% YoY. Strategic collaboration with Regeneron and expanded global operations support guidance for FY 2026 revenue and other income to exceed US $1riginal document: Telix Pharmaceuticals Limited [TLX] Earnings Release — Jul. 20 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 revenue rose 21% YoY to US $247M, with Precision Medicine up 30% YoY. Strategic collaboration with Regeneron and expanded global operations support guidance for FY 2026 revenue and other income to exceed US $1B.
Original document: Telix Pharmaceuticals Limited [TLX] Earnings Release — Jul. 20 2026
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.